Divide and Conquer to Treat Lung Cancer.

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

Who cites it

8 citing papers in PubMed.

1. Enhancer reprogramming underlies therapeutic utility of a SMARCA2 degrader in SMARCA4 mutant cancer.Cell chemical biology · 2024
   Article
2. Blood digital polymerase chain reaction as a potential method to detect human epidermal growth factor receptor 2 amplification in non-small cell lung cancer.Translational lung cancer research · 2021
   Article
3. Patterns of care for older patients with stage IV non-small cell lung cancer in the immunotherapy era.Cancer medicine · 2020
   Article
4. RNA sequencing uncovers the key long non-coding RNAs and potential molecular mechanism contributing to XAV939-mediated inhibition of non-small cell lung cancer.Oncology letters · 2019
   Article
5. Race, Poverty, and Initial Implementation of Precision Medicine for Lung Cancer.Journal of the National Cancer Institute · 2019
   Article
6. Mutations in the SWI/SNF complex induce a targetable dependence on oxidative phosphorylation in lung cancer.Nature medicine · 2018
   Article
7. Implications of the tumor immune microenvironment for staging and therapeutics.Modern pathology : an official journal of the United States and Canadian Academy of Pathology, Inc · 2018
   Review
8. Thoracic Complications of Precision Cancer Therapies: A Practical Guide for Radiologists in the New Era of Cancer Care.Radiographics : a review publication of the Radiological Society of North America, Inc
   Review

Corrections and comments

• Comment on
  Pembrolizumab versus Chemotherapy for PD-L1-Positive Non-Small-Cell Lung Cancer.2016

Authors and funding

1 author.

Funding

Abstract

PubMed holds no abstract for this paper.

Indexed as